Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Cost-effectiveness of abemaciclib plus endocrine therapy in high-risk HR+/HER2–early breast cancer in China

Abstract Objective The aim of this article is to evaluate the cost-effectiveness of abemaciclib plus endocrine therapy (ABE + ET) vs. ET as adjuvant treatment for high-risk hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2–) early breast cancer in China. Metho...

Full description

Bibliographic Details
Main Authors: Qiran Wei, YuTing Xu, Wei Liu, Xin Guan
Format: Article
Language:English
Published: BMC 2023-11-01
Series:Cost Effectiveness and Resource Allocation
Subjects:
Cost-effectiveness
Abemaciclib
Early breast cancer
High risk
Adjuvant treatment
Online Access:https://doi.org/10.1186/s12962-023-00499-9

Internet

https://doi.org/10.1186/s12962-023-00499-9

Similar Items